What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
His primary areas of study are Internal medicine, Cardiology, Heart failure, Myocardial infarction and Quality.
His study in Cardiac resynchronization therapy, Atrial fibrillation, Angina, Randomization and Randomized controlled trial falls within the category of Internal medicine.
Michal Tendera performs multidisciplinary study in Cardiology and Cardiac marker in his work.
He has included themes like Clinical endpoint, Telmisartan and Intensive care medicine in his Heart failure study.
His Myocardial infarction research includes themes of Coronary artery disease, Coronary atherosclerosis, Disease and Depression.
His research integrates issues of Carvedilol, Perindopril, Placebo and Heart disease in his study of Ejection fraction.
His most cited work include:
- 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (11730 citations)
- Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. (4200 citations)
- 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (3099 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Heart failure and In patient.
His Internal medicine study frequently involves adjacent topics like Surgery.
His Percutaneous coronary intervention, Angioplasty, Conventional PCI, Hypertrophic cardiomyopathy and Artery investigations are all subjects of Cardiology research.
His Myocardial infarction research integrates issues from Stroke, Stem cell and Bone marrow.
His Bone marrow research is multidisciplinary, relying on both Progenitor cell and CD34.
Heart failure is closely attributed to Placebo in his research.
He most often published in these fields:
- Internal medicine (65.03%)
- Cardiology (58.17%)
- Myocardial infarction (19.93%)
What were the highlights of his more recent work (between 2010-2021)?
- Internal medicine (65.03%)
- Cardiology (58.17%)
- Myocardial infarction (19.93%)
In recent papers he was focusing on the following fields of study:
Michal Tendera spends much of his time researching Internal medicine, Cardiology, Myocardial infarction, In patient and Heart failure.
Many of his studies on Internal medicine apply to Surgery as well.
His research combines Stem-cell therapy and Cardiology.
Michal Tendera works mostly in the field of Myocardial infarction, limiting it down to concerns involving Bone marrow and, occasionally, Heme oxygenase and Artery.
Specifically, his work in Heart failure is concerned with the study of Cardiac resynchronization therapy.
Michal Tendera combines subjects such as Radiology and Angina with his study of Coronary artery disease.
Between 2010 and 2021, his most popular works were:
- 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (11730 citations)
- 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (3099 citations)
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation (2409 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Cardiology
His main research concerns Internal medicine, Cardiology, Myocardial infarction, Heart failure and Task force.
The study incorporates disciplines such as Preventive healthcare and Specialty in addition to Internal medicine.
His Cardiology study frequently links to related topics such as Clinical endpoint.
His work on Cardiac resynchronization therapy as part of general Heart failure study is frequently linked to Hazard ratio, bridging the gap between disciplines.
His studies examine the connections between Randomized controlled trial and genetics, as well as such issues in Clinical trial, with regards to Physical therapy.
His study in Coronary artery disease is interdisciplinary in nature, drawing from both Fractional flow reserve, Radiology, Incidence and Angina.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
